If MNKD can sell 150M shares to some big investors or a potential partner, it will be a big boost to its share price. With the potential of Afrezza, dilution is not an issue. It will put the concern about BK away.
Matt said Sanofi primarily targeted T2 patients, which was totally wrong. It should start with T1 patients as T1 patients already familiar with insulin usage, and many have CGM. It's much easier to T1 to master the usage of Afrezza and see the advantage.
New article on Marketwatch.
It didn't mention which company's hTERT vaccine is used. Guess?
This could be Al's idea to create diabetic care center with new treatment protocol.
Or it could mean that a small improvement during the acute phase can result in much significant benefit over long term.